# Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression

> **NCT04040725** · PHASE2 · WITHDRAWN · sponsor: **Dana-Farber Cancer Institute**

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Rogaratinib

## Key facts

- **NCT ID:** NCT04040725
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-11-27
- **Primary completion:** 2019-11-27
- **Final completion:** 2019-11-27
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawn per Bayer
- **Last updated:** 2019-12-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04040725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04040725, "Rogaratinib for BCG Refractory High Risk Non-Muscle Invasive Bladder Cancer With FGFR1/2 Overexpression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04040725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*